NF‐κB pathway: a target for preventing β‐amyloid (Aβ)‐induced neuronal damage and Aβ42 production
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Beta‐amyloid (Aβ) peptides are key proteins in the pathophysiology of Alzheimer's disease (AD). While Aβ42 aggregates very rapidly to form early diffuse plaques, supplemental Aβ40 deposition is required to form mature neuritic plaques. We here investigated the role of nuclear factor‐κB (NF‐κB) pathway in Aβ40‐mediated neuronal damage and amyloid pathology. In rat primary neurons and human postmitotic neuronal cells, the Aβ peptide induced a dose‐dependent neuronal death, reduced the levels of the anti‐apoptotic protein Bcl‐X L , enhanced the cytosolic release of cytochrome c, and elicited the intracellular accumulation and secretion of Aβ42 oligomers. Moreover, Aβ40 activated the NF‐κB pathway by selectively inducing the nuclear translocation of p65 and p50 subunits, and promoted an apoptotic profile of gene expression. As inhibitors of the NF‐κB pathway, we tested the capability of a double‐stranded κB decoy oligonucleotide, the anti‐inflammatory drug aspirin and the selective IκB kinase 2 inhibitor, AS602868, to modify the Aβ40‐mediated effects. These treatments, transiently applied before Aβ exposure, completely inhibited p50/p65 nuclear translocation and neuronal damage. The κB decoy also inhibited the Aβ‐induced release of cytochrome c, restored the levels of Bcl‐X L , and prevented intraneuronal accumulation and secretion of Aβ42. These results open up interesting perspectives on the development of novel strategies targeting out NF‐κB p50/p65 dimers for pharmacological intervention in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 4×
“…the amyloidogenic APP processing occurs even in normal conditions, diverse genetic defects causing inherited AD have been shown to augment it, leading to the hypothesis that increased Ab production and ⁄ or failure of Ab clearance mechanisms might be key pathogenetic steps in AD (Selkoe, 2002a).”
BackgroundInfluentialTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Shimizu, S., Narita, M., Tsujimoto, Y., & Tsujimoto, Y. (1999) · Nature · doi:10.1038/20959 · Cited by 2,178 · cited 1×
“It is generally accepted that Bcl-XL preserves cell survival by controlling mitochondrial membrane ion permeability and cytochrome c release into the cytosol (Shimizu et al., 1999).”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“Indeed, a subset of non-steroidal anti-inflammatory drugs also affects amyloid production, by reducing the secretion of Ab42 from cultured cells, independently of their effects on cyclooxygenase activity (Weggen et al., 2001; Sagi et al., 2003).”
BackgroundNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
NF-kB: a crucial transcription factor for glial and neuronal cell function
O'Neill, L. A. J., & Kaltschmidt, C. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01035-1 · Cited by 1,013
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 2×
“A matter of controversy is whether the pathological cascade is initiated by intraneuronal accumulation of Ab or by augmented Ab levels in the extracellular space (Gouras et al., 2000; Kienlen-Campard et al., 2002; Selkoe, 2002b; Meyer-Luehmann et al., 2003; Oddo et al., 2003).”
BackgroundPike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699
Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., & Goldstein, L. S. B. (2001) · Nature · doi:10.1038/414643a · Cited by 583 · cited 3×
“The intracellular Ab42 was then detected by immunoblot analysis using an end-specific Ab42 antibody (Kamal et al., 2001) (Fig.”
MethodInfluential
Cited by
NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review
Shih, R.-H., Wang, C.-Y., & Yang, C.-M. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00077 · Cited by 910
Sivandzade, F., Prasad, S., Bhalerao, A., & Cucullo, L. (2019) · Redox Biology · doi:10.1016/j.redox.2018.11.017 · Cited by 639
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Maalouf, M., Rho, J. M., & Mattson, M. P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.002 · Cited by 574
Microglial cell dysregulation in brain aging and neurodegeneration
von Bernhardi, R., Eugenín-von Bernhardi, L., & Eugenín, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00124 · Cited by 556
The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
Sun, E., Motolani, A., Campos, L., & Lu, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168972 · Cited by 361
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Neuroinflammation in Alzheimer’s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 270
The duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 190
Involvement of Environmental Mercury and Lead in the Etiology of Neurodegenerative Diseases
Monnet-Tschudi, F., Zurich, M.-G., Boschat, C., Corbaz, A., & Honegger, P. (2006) · Reviews on Environmental Health · doi:10.1515/reveh.2006.21.2.105 · Cited by 176
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
Srinivasan, M., & Lahiri, D. K. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.989834 · Cited by 164
“Sodium salicylate, an NSAID has been shown to block Ab-induced human APOE upregulation in astroglial cells by blocking NF-kB [23].”
BackgroundInfluentialRole of TGFβ signaling in the pathogenesis of Alzheimer’s disease
von Bernhardi, R., Cornejo, F., Parada, G. E., & Eugenín, J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00426 · Cited by 149
“In fact, Aβ can be a strong inducer of NFκB in neuron cell death via the induction of intracellular ROS (Lee et al., 2005b; Valerio et al., 2006), and through tumor necrosis factor receptor 1 (TNFR1) signaling, which result in neuronal apoptosis (Li et al., 2004; Valerio et al., 2006).”
BackgroundCarrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
Upstream regulators and downstream effectors of NF-κB in Alzheimer’s disease
Shi, Z.-M., Han, Y.-W., Han, X.-H., Zhang, K., Chang, Y.-N., Hu, Z.-M., Qi, H.-X., Ting, C., Zhen, Z., & Hong, W. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.05.022 · Cited by 125
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases
Thapa, K., Khan, H., Sharma, U., Grewal, A. K., & Singh, T. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118975 · Cited by 92
Geng, L., Zhang, T., Liu, W., & Chen, Y. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.9.1096 · Cited by 65
Rastegar-Moghaddam, S. H., Ebrahimzadeh-Bideskan, A., Shahba, S., Malvandi, A. M., & Mohammadipour, A. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01200-z · Cited by 64
Jin, P., Kim, J.-A., Choi, D.-Y., Lee, Y.-J., Jung, H. S., & Hong, J. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-2 · Cited by 59
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Guha, S., Paidi, R. K., Goswami, S., Saha, P., & Biswas, S. C. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.11.021 · Cited by 26
Jo, M.-R., Park, M.-H., Choi, D.-Y., Yuk, D.-Y., Lee, Y.-M., Lee, J.-M., Jeong, J.-H., Oh, K.-W., Lee, M.-S., Han, S.-B., et al. (2011) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2011.19.3.288 · Cited by 18
“NF-κB can be activated via induction of intracellular ROS (Hong et al., 2000; Valerio et al., 2006).”
Background
Metadata
- Authors
- Valerio, A., Boroni, F., Benarese, M., Sarnico, I., Ghisi, V., Bresciani, L. G., Ferrario, M., Borsani, G., Spano, P., & Pizzi, M.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2006-04
- Volume
- 23
- Issue
- 7
- Pages
- 1711-1720
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W1483432124
- Cited by
- 148
- References
- 17
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.